CONTINUING MEDICAL EDUCATION

2016 Pacific Northwest Annual Workshop on Methods in Radiation Oncology Clinical Trials

MAY 5–7, 2016
Collaborative Life Sciences Building
Portland, Ore.
TARGET AUDIENCE
Radiation oncology physicians, residents, fellows and junior faculty

OBJECTIVES
Following this CME course, participants should be able to demonstrate the following:

• An ability to define primary and secondary trial aims and appropriate endpoints to measure in radiotherapy clinical trials.

• An ability to define Phase 0, I, II, III, and other clinical trial designs for radiotherapy clinical trials.

• An understanding of the basic clinical trial biostatistics.

• Knowledge of the best practices for image guidance-driven clinical trials.

• An understanding of how to incorporate immune-based endpoints in radiotherapy clinical trial design.

• An understanding of how to incorporate QOLife endpoints in radiotherapy clinical trial design.

• An understanding of the role of clinical informatics in radiotherapy clinical trial design.

• Knowledge of best practices in particle therapy-based clinical trial design.
Faculty

COURSE DIRECTORS
Charles R. Thomas Jr., M.D.
Professor and Chair
Department of Radiation Medicine
OHSU Knight Cancer Institute

Ramesh Rengan, M.D., Ph.D.
Course Co-Director
Medical Director
Seattle Cancer Care Alliance Proton Therapy

Mohamed Khan, M.D., Ph.D.
Course Co-Director
Leader of Radiation Oncology
British Columbia Cancer Agency
Associate Professor
University of British Columbia

OHSU FACULTY
Archie Bleyer, M.D., F.R.C.P.
Adjunct Faculty
Clinical Research Professor
Department of Radiation Medicine
OHSU Knight Cancer Institute

Sophia Bornstein, M.D., Ph.D.
Physician-Scientist
Department of Radiation Medicine
OHSU Knight Cancer Institute

Alex Guimaraes, M.D., Ph.D.
Associate Professor and Section Head
Abdominal Imaging Diagnostic Radiology
OHSU

Arthur Y. Hung, M.D.
Assistant Professor
Medical Student Clerkship Medicine Director
Department of Radiation Medicine
OHSU Knight Cancer Institute

Jerry Jaboin, M.D., Ph.D.
Assistant Professor
Department of Radiation Medicine
OHSU Knight Cancer Institute

Elena Korngold, M.D.
Associate Professor
Department of Diagnostic Radiology
OHSU

John Minger
Senior Research Assistant
Department of Radiation Medicine
OHSU Knight Cancer Institute

Timur Mitin, M.D., Ph.D.
Assistant Professor
Department of Radiation Medicine
OHSU Knight Cancer Institute
Medical Director
Tuality/OHSU Cancer Center

VISITING FACULTY
Marka Crittiden, M.D., Ph.D.
Physician-Scientist
Department of Radiation Oncology
The Oregon Clinic

Clifton David Fuller, M.D., Ph.D.
Assistant Professor
Department of Radiation Oncology
The University of Texas MD Anderson Cancer Center

Michael Gough, Ph.D.
Scientist
Earle A. Chiles Research Institute

Lilie L. Lin, M.D.
Assistant Professor
Department of Radiation Oncology
Hospital of the University of Pennsylvania

James Moon, M.S.
Biostatistician
Fred Hutchinson Cancer Research Center

Javier F. Torres-Roca, M.D.
Associate Member
Research and Clinical Trials
Moffitt Cancer Center

Andrew Trister, M.D., Ph.D.
Postdoctoral Fellow
Sage Bionetworks
Resident Physician

Kristina Young, M.D., Ph.D.
Department of Radiation Oncology
The Oregon Clinic
HOW TO ENROLL
Tuition: $400 Practicing physicians
$350 Residents/fellows
Payment can be made by Visa, MasterCard or check.
Register online at www.ohsuknightcancer.com/radcme
Advanced registration closes April 26, 2016.

GENERAL CONTACT INFORMATION
e: cme@ohsu.edu
p: 503 494-8700
f: 503 494-0392
Continuing Medical Education, L-602
Oregon Health & Science University
3181 S.W. Sam Jackson Park Rd.
Portland, OR 97239

For registration questions, please contact:
Bridgett Sparkman
e: sparkmab@ohsu.edu
p: 503 494-1998

DIRECTIONS
www.ohsu.edu/directions

CONFERENCE LOCATION
The course will be held in the Collaborative Life Sciences Building, located in Portland’s South Waterfront district, a short tram ride to the main OHSU campus on Marquam Hill.
Collaborative Life Sciences Building, 2370 S.W. Moody Ave. Portland, OR 97239

OHSU KNIGHT CANCER INSTITUTE
With the latest treatments, technologies and clinical trials, we are the only clinical cancer center in Oregon designated by the National Cancer Institute — an honor earned only by the nation’s top cancer centers.

ACCOMMODATIONS
Participants may stay in the Residence Inn Riverplace in Downtown Portland, located near Tom McCall Waterfront Park and within walking distance to Portland’s city center. The Inn provides spacious suites with all the comforts of home and a complimentary hot breakfast buffet. Guests can enjoy walking along the Willamette River, taking the Portland Streetcar to visit many downtown Portland attractions or viewing the city via the Portland Aerial Tram. The hotel is just minutes from OHSU and the Collaborative Life Sciences Building.

To make your reservation, please call 503 552-9500.
THURSDAY, MAY 5
6:30 p.m. Registration
7-8  p.m. Welcome, course overview and pre-test
Charles Thomas, M.D.
Ramesh Rengan, M.D., Ph.D.
Mohamed Khan, M.D., Ph.D.

FRIDAY, MAY 6
7 a.m. Registration/continental breakfast
8 a.m. Responsibilities of the PI
Charles R. Thomas, M.D.
8:20 a.m. Primer on Biostatistics for Clinical Trials
James Moon, M.S.
9 a.m. Phase I-II Radiotherapy-based Clinical Trials:
Design and Endpoints
Ramesh Rengan, M.D., Ph.D.
9:45 a.m. Image-guided Radiotherapy Clinical Trial Design
Dave Fuller, M.D., Ph.D.
10:20 a.m. Coffee break and poster review of clinical trials
11 a.m. Imaging Endpoints in Clinical Trials:
RESIST, PERSIST and Beyond
Elena Korngold, M.D.
11:30 a.m. Design of Parallel Pathology and Imaging Endpoints
in Radiotherapy-based Clinical Trials
Kristina Young, M.D., Ph.D.
Noon Lunch
1 p.m. Discussion of concept sheets
Open discussion
1:45 p.m. Incorporation of Novel Translational Research Endpoints
in Clinical Trials
Mohamed Khan, M.D., Ph.D.
2:10 p.m. Immune-Based Endpoints in Radiotherapy-based Clinical Trials
Marka Crittiden, M.D., Ph.D.; Michael Gough, Ph.D.
2:45 p.m. Normal Tissue Considerations in Design of Radiotherapy
Trial Design
Charles Thomas, M.D.
3:20 p.m. Radiosensitivity and Radioresistance Prediction Tools in Trials
Javier Torres-Roca, M.D.
4 p.m. Panel #1
5 p.m. Adjourn
SATURDAY, MAY 7

7:45 a.m.        Continental breakfast

8:25 a.m.        Clinical Informatics in Radiotherapy Trial Design  
                  Dave Fuller, M.D., Ph.D.

9:05 a.m.        Particle Therapy-Based Clinical Trial Design  
                  Ramesh Rengan, M.D., Ph.D.

9:45 a.m.        QOLife Endpoints in Clinical Trial Design  
                  Lilie Lin, M.D.

10:25 a.m.       Mathematical Modeling in Design of Radiotherapy  
                  Time-Dose-Fractionation  
                  Andrew Trister, M.D., Ph.D.

11:05 a.m.       Role of the Research Associate in Radiotherapy Clinical Trials

11:30 a.m.       Lunch

12:30 p.m.       Clinical Trial Design breakout sessions (disease oriented)

Session 1        GU Radiotherapy  
                  Timur Mitin, M.D., Ph.D.

Session 2        GI Radiotherapy  
                  Charles Thomas, M.D.

Session 3        Soft Tissue and Bone Tumor  
                  Arthur Hung, M.D.

Session 4        Pediatric Oncology  
                  Archie Bleyer, M.D., F.R.C.P.

Session 5        Lung Radiotherapy  
                  Ramesh Rengan, M.D., Ph.D.

Session 6        Head and Neck  
                  Dave Fuller, M.D., Ph.D.

Session 7        Palliative Radiotherapy  
                  Sophia Bornstein, M.D., Ph.D.

Session 8        CNS Radiotherapy  
                  Jerry Jaboin, M.D.

1:30 p.m.        Panel #2

2 p.m.           Post-session test and adjourn

Airport shuttles